FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309027512> ?p ?o ?g. }

• W4309027512 endingPage "1180" @default.
• W4309027512 startingPage "1180" @default.
• W4309027512 abstract "Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) is a heterogeneous disease. To date, more than ninety ALK fusions in lung cancer have been found. Here, we report for the first time a rare LOC388942-ALK fusion in NSCLC was sensitive to crizotinib but resistant to the sequential ceritinib and alectinib and acquired classical ALK G1202R resistance mutation after long-term treatment with anlotinib. This case highlights dynamic monitoring of gene alteration using next-generation sequencing (NGS) is necessary during the anti-tumor process.A 55-year-old male, with no history of smoking history and no family history of cancer, was found malignant pleural effusion and multiple metastasis nodules in the left lung. He was histopathologically diagnosed with ALK-positive cT4N0M1a adenocarcinoma in June 2016. NGS of the tumor identified a rare LOC388942-ALK fusion (L intergenic: A 20, 1.41%). Then, the patient was treated with chemotherapy, crizotinib, ceritinib, alectinib, and anlotinib sequentially. The patient achieved partial response (PR) to chemotherapy and crizotinib. No evidence of a secondary resistant molecular event was found after resistance to crizotinib, ceritinib, or Alectinib. After 8 months of alectinib treatment, the tumor gradually enlarged again. Anlotinib was followed for 13 months. Thirteen months later, new lesions in the lower lobe of the right lung appeared and increased gradually, indicating definite progression of the tumor. Classical ALK G1202R resistance mutations was detected using cfDNA NGS. The patient refused to receive lorlatinib targeting G1202R resistance mutations and continued with anlotinib. He dead in August 2022, achieving 5-year overall survival (OS).Distinct ALK fusions in NSCLC have different cancer biology, leading to different response to ALK tyrosine kinase inhibitors (ALK-TKIs), even developed different resistance mechanism. Reporting the clinical details of rare ALK fusions in NSCLC is necessary to guide the treatment for clinicians and researchers." @default.
• W4309027512 created "2022-11-21" @default.
• W4309027512 creator A5008184651 @default.
• W4309027512 creator A5010238813 @default.
• W4309027512 creator A5021078253 @default.
• W4309027512 creator A5024474468 @default.
• W4309027512 creator A5043871151 @default.
• W4309027512 creator A5047455588 @default.
• W4309027512 creator A5066956711 @default.
• W4309027512 creator A5077752488 @default.
• W4309027512 creator A5088868208 @default.
• W4309027512 date "2022-11-01" @default.
• W4309027512 modified "2023-09-27" @default.
• W4309027512 title "Classical ALK G1202R resistance mutation was identified in a lung adenocarcinoma patient with rare LOC388942-ALK fusion after sequential treatment with ALK-TKIs and anlotinib: a case report" @default.
• W4309027512 cites W1974903221 @default.
• W4309027512 cites W1995641421 @default.
• W4309027512 cites W2050249255 @default.
• W4309027512 cites W2166292499 @default.
• W4309027512 cites W2172010139 @default.
• W4309027512 cites W2345442866 @default.
• W4309027512 cites W2482427906 @default.
• W4309027512 cites W2581592505 @default.
• W4309027512 cites W2624310346 @default.
• W4309027512 cites W2765831845 @default.
• W4309027512 cites W2785110924 @default.
• W4309027512 cites W2789601608 @default.
• W4309027512 cites W2805354595 @default.
• W4309027512 cites W2885596446 @default.
• W4309027512 cites W2894476389 @default.
• W4309027512 cites W2899668190 @default.
• W4309027512 cites W2901829617 @default.
• W4309027512 cites W2920889549 @default.
• W4309027512 cites W2923683745 @default.
• W4309027512 cites W2990222327 @default.
• W4309027512 cites W3007188668 @default.
• W4309027512 cites W3007475361 @default.
• W4309027512 cites W3190602458 @default.
• W4309027512 cites W4229376968 @default.
• W4309027512 doi "https://doi.org/10.21037/atm-22-5194" @default.
• W4309027512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36467355" @default.
• W4309027512 hasPublicationYear "2022" @default.
• W4309027512 type Work @default.
• W4309027512 citedByCount "2" @default.
• W4309027512 countsByYear W43090275122023 @default.
• W4309027512 crossrefType "journal-article" @default.
• W4309027512 hasAuthorship W4309027512A5008184651 @default.
• W4309027512 hasAuthorship W4309027512A5010238813 @default.
• W4309027512 hasAuthorship W4309027512A5021078253 @default.
• W4309027512 hasAuthorship W4309027512A5024474468 @default.
• W4309027512 hasAuthorship W4309027512A5043871151 @default.
• W4309027512 hasAuthorship W4309027512A5047455588 @default.
• W4309027512 hasAuthorship W4309027512A5066956711 @default.
• W4309027512 hasAuthorship W4309027512A5077752488 @default.
• W4309027512 hasAuthorship W4309027512A5088868208 @default.
• W4309027512 hasBestOaLocation W43090275121 @default.
• W4309027512 hasConcept C117643217 @default.
• W4309027512 hasConcept C121608353 @default.
• W4309027512 hasConcept C126322002 @default.
• W4309027512 hasConcept C143998085 @default.
• W4309027512 hasConcept C2776232967 @default.
• W4309027512 hasConcept C2776256026 @default.
• W4309027512 hasConcept C2778347629 @default.
• W4309027512 hasConcept C2779220645 @default.
• W4309027512 hasConcept C2779422266 @default.
• W4309027512 hasConcept C2779750558 @default.
• W4309027512 hasConcept C2781182431 @default.
• W4309027512 hasConcept C502942594 @default.
• W4309027512 hasConcept C71924100 @default.
• W4309027512 hasConceptScore W4309027512C117643217 @default.
• W4309027512 hasConceptScore W4309027512C121608353 @default.
• W4309027512 hasConceptScore W4309027512C126322002 @default.
• W4309027512 hasConceptScore W4309027512C143998085 @default.
• W4309027512 hasConceptScore W4309027512C2776232967 @default.
• W4309027512 hasConceptScore W4309027512C2776256026 @default.
• W4309027512 hasConceptScore W4309027512C2778347629 @default.
• W4309027512 hasConceptScore W4309027512C2779220645 @default.
• W4309027512 hasConceptScore W4309027512C2779422266 @default.
• W4309027512 hasConceptScore W4309027512C2779750558 @default.
• W4309027512 hasConceptScore W4309027512C2781182431 @default.
• W4309027512 hasConceptScore W4309027512C502942594 @default.
• W4309027512 hasConceptScore W4309027512C71924100 @default.
• W4309027512 hasIssue "21" @default.
• W4309027512 hasLocation W43090275121 @default.
• W4309027512 hasLocation W43090275122 @default.
• W4309027512 hasLocation W43090275123 @default.
• W4309027512 hasOpenAccess W4309027512 @default.
• W4309027512 hasPrimaryLocation W43090275121 @default.
• W4309027512 hasRelatedWork W2529194187 @default.
• W4309027512 hasRelatedWork W2533300620 @default.
• W4309027512 hasRelatedWork W2624310346 @default.
• W4309027512 hasRelatedWork W2740978652 @default.
• W4309027512 hasRelatedWork W2758151171 @default.
• W4309027512 hasRelatedWork W2797353951 @default.
• W4309027512 hasRelatedWork W2954772194 @default.
• W4309027512 hasRelatedWork W2987457019 @default.
• W4309027512 hasRelatedWork W3044516145 @default.
• W4309027512 hasRelatedWork W3107281819 @default.
• W4309027512 hasVolume "10" @default.

• next